IP Watchdog

AUGUST 14, 2021

Despite India’s progress in many areas, from science to literature to technology, protection for intellectual property rights (IPR) is a topic that has come under scrutiny. The IP laws in India have remained vastly unchanged and unreviewed over the past few decades.

Pharmaceuticals 130

Pharmaceuticals Technology 130

IP Watchdog

APRIL 3, 2023

The Information Technology and Innovation Foundation (ITIF) is hosting an event on the downfall of Japan’s pharmaceutical industry. This week in Washington IP news, Congress is out of town thanks to a state work period, but there are still several interesting events related to the IP world.

Pharmaceuticals 59

Pharmaceuticals Technology 59

IP Watchdog

AUGUST 30, 2024

This week in Other Barks & Bites: The World Intellectual Property Office (WIPO) releases a list of the top technology clusters in the world; La Jolla Pharmaceuticals files lawsuit against USPTO to revive shock therapy patent; Romania joins the Unitary Patent System; "very demure, very mindful" trend leads to trademark drama.

Technology 59

Technology Pharmaceuticals 59

IP Watchdog

FEBRUARY 2, 2023

The key data being questioned is that of the Initiative for Medicines, Access & Knowledge (I-MAK), an advocacy organization that has become a “principal, go-to source” for data on the number of patents and patent applications covering pharmaceutical innovations.

Pharmaceuticals 119

Pharmaceuticals Technology 119

IP Watchdog

APRIL 29, 2024

The COVID-19 vaccine was quickly rolled out compared to other vaccines in the past and many pharmaceutical companies benefited financially. However, GSK contends their competitors, Pfizer Inc. and Pharmacia & Upjohn Co. LLC (collectively Pfizer) and BioNTech SE, BioNTech Manufacturing GMBH and BioNTech US Inc.

Manufacturing 111

Manufacturing Pharmaceuticals Technology Litigation 111

Complex Discovery

NOVEMBER 26, 2024

Editor’s Note: Navigating the fine line between thoughtful gestures and ethical missteps in the legal technology industry has never been more critical. As the legal technology industry continues to evolve, the need for clear guidelines on accepting gifts, trips, passes, and donations from vendors becomes increasingly urgent.

Technology 59

Technology Government and Public Sector Education Pharmaceuticals 59

IP Watchdog

MARCH 28, 2022

innovation leadership; the Hudson Institute takes a look at new challenges to copyright law posed by the digital publishing industry; and the Information Technology & Innovation Foundation looks to correct misconceptions in the advocacy for exercising march-in rights under Bayh-Dole as a price control mechanism for pharmaceuticals.

Pharmaceuticals 98

Pharmaceuticals Technology 98

IP Watchdog

OCTOBER 24, 2022

Two major trade organizations representing global vaccine manufacturers are officially backing a proposal submitted to the G20 and G7 countries in July that they claim offers practical solutions for future pandemics to avoid the inequities that have been highlighted by the COVID-19 pandemic.

Manufacturing 113

Manufacturing Pharmaceuticals Technology 113

InHouseBlog

APRIL 8, 2022

Technology Transactions Attorney , Starkey Legal Search (Remote). Corporate Counsel – Technology , Lowe’s Companies, Inc. Commercial/Technology Counsel , Grayson Allen, Inc. Senior Director, Compliance Risk Navigation , Regeneron Pharmaceuticals (Tarrytown, NY). Commercial Counsel , Sourcegraph (Remote).

Real Estate 97

Real Estate Pharmaceuticals Litigation Technology 97

IP Watchdog

OCTOBER 20, 2022

The People’s Vaccine Alliance, a coalition of over 100 organizations, issued a statement this week alleging that the pharmaceutical industry is attempting to tighten its control of the world’s pandemic response plans.

Pharmaceuticals 81

Pharmaceuticals Manufacturing Technology Litigation 81

Complex Discovery

JULY 28, 2024

The publication selects five top articles to keep legal, business, and technology professionals informed about key developments in cyber discovery, data discovery, and legal discovery. By transforming these developments into informational news briefs, the newsletter provides readers with a nuanced perspective for strategic decision-making.

Discovery 97

Discovery Government and Public Sector Pharmaceuticals Technology 97

IP Watchdog

JULY 13, 2023

The district court’s decision highlights a clear tension between claim construction and enablement that, if left to stand, could permit pharmaceutical companies to block lower-cost generic medications with patents they did not actually invent.

Technology 52

Technology Pharmaceuticals Construction Evidence 52

IP Watchdog

FEBRUARY 6, 2023

Case law has defined prosecution laches as an affirmative defense against an infringement assertion. Specifically, the case law indicates a patent that is being asserted is unenforceable when the patentee caused an unreasonable and unexplained delay in prosecution of the patent. Symbol Tech v Lemelson Medical, No. 04-1451 (Fed.

Pharmaceuticals 69

Pharmaceuticals Case Law Technology 69

IP Watchdog

FEBRUARY 10, 2023

This week in Other Barks & Bites: The Senate Judiciary Committee passes a number of bills that aim to reduce drug prices and anticompetitive practices by pharmaceutical companies; the USPTO opens its nomination period for a prestigious technology award; the U.S.

Pharmaceuticals 59

Pharmaceuticals Technology 59

IP Watchdog

MAY 10, 2023

Mylan Pharmaceuticals petitioned the PTAB for inter partes review (IPR) of all 18 claims in Sanofi’s drug injector pen patent. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision Tuesday that reversed a Patent Trial and Appeal Board (PTAB) decision invalidating claims of Sanofi’s U.S.

Pharmaceuticals 75

Pharmaceuticals Litigation Technology 75

IP Watchdog

APRIL 24, 2024

While the WHO pandemic agreement has been met with widespread support from many of the international agency’s member nations, including the United States, it retains provisions limiting intellectual property (IP) rights that have encouraged opposition from lawmakers and pharmaceutical innovators alike.

Pharmaceuticals 59

Pharmaceuticals Technology 59

IP Watchdog

AUGUST 12, 2024

Teva Pharmaceuticals (2019), the Federal Circuit rejected Celanese’s contentions that statutory changes wrought by the America Invents Act (AIA) altered the on-sale bar such that sales of products manufactured by an undisclosed process would not invalidate patents claiming that process. Following the U.S.

Pharmaceuticals 64

Pharmaceuticals Healthcare Manufacturing Technology 64

IP Watchdog

FEBRUARY 23, 2024

While this 12th version of the GIPC’s index noted some positive developments in national IP frameworks, stagnation among the recurring leaders of the IP Index is a major concern given growing efforts by governments to control prices in critical sectors of the economy, especially in pharmaceuticals.

Pharmaceuticals 59

Pharmaceuticals Technology 59

Complex Discovery

NOVEMBER 3, 2024

The podcast provides an automated yet insightful look at AI’s evolving impact, enriching the way information is consumed and discussed within the legal technology field. Additionally, October marked five years since Mary Mack and Kaylee Walstad acquired the EDRM. Partnerships played an essential role in October’s updates as well.

Government and Public Sector 69

Government and Public Sector Technology Cross-Examination Energy and Utilities 69

IP Watchdog

AUGUST 26, 2021

The patent generally covers cancer immunotherapy technology. The case relates to U.S. 7,446,190, owned by Sloan Kettering, which is titled “Nucleic Acids Encoding Chimeric T Cell Receptors.” Juno sued Kite Pharma, Inc. for infringement of the ‘190 patent through the sale of its YESCARTA product.

Trial Brief 122

Trial Brief Evidence Technology Pharmaceuticals 122

IP Watchdog

AUGUST 2, 2023

On July 31, the National Institutes of Health (NIH) hosted a virtual workshop titled Transforming Discoveries into Products: Maximizing NIH’s Levers to Catalyze Technology Transfer.

Discovery 91

Discovery Technology Pharmaceuticals 91

Complex Discovery

OCTOBER 15, 2024

The report also underscores the agencies’ strengthened enforcement efforts, with 28 merger challenges in key sectors like healthcare, technology, and consumer goods. These enforcement actions targeted critical sectors, including pharmaceuticals, healthcare, technology, and energy. of the total​.

Pharmaceuticals 59

Pharmaceuticals Healthcare Technology Manufacturing 59

CaseFox

NOVEMBER 27, 2023

From the traditional focus on environmental and occupational hazards to the exploration of new frontiers in pharmaceuticals and consumer products. Cases related to pharmaceutical drugs, consumer products, and emerging contaminants in drinking water are gaining prominence.

Litigation 52

Litigation Pharmaceuticals Expert Testimony Evidence 52

Next Generation E-Discovery Law & Tech Blog

AUGUST 27, 2024

Leveraging X1’s unique and patented in-place indexing technology, data extraction becomes highly targeted, allowing for efficient responses to litigation holds. Client Example: • Overview: A major pharmaceutical retailer uses X1 within Relativity to perform 50 data collections weekly, covering both Mac and PC environments.

Litigation 59

Litigation Pharmaceuticals Retail Technology 59

Complex Discovery

FEBRUARY 12, 2025

The technology, healthcare, and financial services sectors continue to be the most active in corporate transactions, each influenced by unique market drivers, regulatory challenges, and digital transformation initiatives. Understanding the key trends within these industries is essential for navigating the evolving M&A landscape in 2025.

Healthcare 52

Healthcare Pharmaceuticals Technology Manufacturing 52

IP Watchdog

JULY 12, 2022

The use of this document is expected to streamline communications between the USPTO and patent applicants regarding delays in patent prosecution and also save agency resources by reducing manual review of PTA statements and leveraging information technology (IT) resources at the agency for automatically detecting and reviewing such statements.

Technology 59

Technology Pharmaceuticals 59

Complex Discovery

MARCH 5, 2025

Pharmaceuticals have been tested primarily on men, resulting in higher risks of adverse effects for women. Office temperatures are calibrated to male metabolic rates, leaving women uncomfortably cold and workplaces inefficient.

Media and Entertainment 52

Media and Entertainment Education Pharmaceuticals Technology 52

Complex Discovery

MARCH 12, 2025

The deal volume reflects not only a strong appetite for growth but also the pressure businesses face to adapt to evolving technologies, regulatory landscapes, and competitive pressures. The answer is multi-facetedeconomic trends, technological advancements, and shifting regulatory landscapes are all playing a role.

Technology 52

Technology Pharmaceuticals Healthcare Litigation 52

IP Watchdog

APRIL 18, 2023

The Council for Innovation Promotion (C4IP) on Monday held a webinar featuring some big names in the IP world to clear up what the organization characterizes as misguided views on the use of Title 28 of the U.S. Code, Section 1498(a). The event was prompted in part by a recent U.S. s COVID-19 vaccine.

Manufacturing 128

Manufacturing Pharmaceuticals Technology Litigation 128

The Cloud Court Blog

OCTOBER 26, 2022

Which is why we’ve built a whole suite of proprietary deposition technologies to enable you and your aligned teams to win by spotting gorillas hiding in deposition data. We’ll be happy to give you a sneak peek at our technology. And above all, with winning cases. That’s why our tag line is: Litigate Like You Mean It.

Depositions 52

Depositions Witnesses Exhibits Objections 52

IP Watchdog

JUNE 27, 2022

A terrible idea – wayward and ill-conceived, criticized by all economic, political and geopolitical fronts – has come to fruition. The World Trade Organization’s (WTO) TRIPs waiver on patents related to COVID-19 vaccines will disincentivize the entire industry from investing in vaccine production.

Pharmaceuticals 123

Pharmaceuticals Technology 123

IP Watchdog

MAY 23, 2024

On May 20, the Council for Innovation Promotion (C4IP) sent a letter addressed to the U.S. Senate Committee on the Judiciary one day before the committee held a hearing on competition and consumer pricing in the prescription drug market.

Pharmaceuticals 105

Pharmaceuticals Technology 105

IP Watchdog

JULY 1, 2024

Chamber of Commerce today responded to a recent U.S. Patent and Trademark Office (USPTO) report that the Chamber says proves much of the data that is often cited as proof of life sciences companies abusing the patent system is “more fiction than truth.”

Pharmaceuticals 64

Pharmaceuticals Litigation Technology 64

IP Watchdog

MARCH 30, 2023

A bipartisan group of congress members sent a letter to U.S. Patent and Trademark Office Director Kathi Vidal late last week urging her to implement some of the proposals outlined in her October 2022 Request for Comments on Robust and Reliable Patents in order to address problems around drug pricing.

Pharmaceuticals 69

Pharmaceuticals Technology 69

Attorney at Work

MAY 30, 2022

Let’s say you’re a trade secrets lawyer, and the problem that triggers demand for you is that of talent moving from one technology company to another, taking with them proprietary information stored in their brains. How to Introduce Yourself as a Lawyer—A Few Examples. Rachel: “Sounds exciting.

Pharmaceuticals 246

Pharmaceuticals Manufacturing Evidence Technology 246

Complex Discovery

JUNE 17, 2024

This case highlights critical issues surrounding product safety, transparency, and the ethical responsibilities of corporations, especially within the pharmaceutical industry. The broader implications of this settlement will likely influence similar litigations and regulatory practices in the pharmaceutical and consumer goods industries.

Litigation 111

Litigation Pharmaceuticals Manufacturing Evidence 111

IP Watchdog

JUNE 14, 2023

Earlier this week, the Information Technology and Innovation Foundation (ITIF) released a report that offers a rebuttal to nine claims it identifies with the “anti-IP progressive orthodoxy.”

Rebuttal 98

Rebuttal Pharmaceuticals Technology 98